比佛拉唑(Bifonazole,Mycospor)是一种新型局部抗真菌药物。为全面评价国产比佛拉唑抗真菌功效,进行了液基法药敏试验及动物和临床的试验治疗,兹报告如下: 1 材料与方法 1.1 液基法敏感性试验 采用沙氏液基(pH 6.8～7.0)及本科真菌室保留的12种真菌。药物原粉由重庆西南制药一厂生产,纯度>99％。药物用95％乙醇溶解,液基的药物浓度梯度为:128—64—32—16—8—4—2—1—0.5—0.25 Bifonazole (Mycospor) is a new topical antifungal drug. In order to comprehensively evaluate the antifungal efficacy of domestic bevacizumab, we conducted liquid-based drug susceptibility testing and animal and clinical trial treatment. We report the following: 1 Materials and methods 1.1 The liquid-based method sensitivity test uses the liquid-base pH 6.8 ~ 7.0) and 12 kinds of fungi retained in undergraduate fungal chamber. The medicine powder is produced by Chongqing No.1 Southwest Pharmaceutical Factory with purity> 99%. The drug was dissolved in 95% ethanol and the liquid-based drug concentration gradient was: 128-64-32-16-8-4-2-1-0.5-0.25